GENERAL MEETING OF SHAREHOLDERS
The Combined General Meeting of Shareholders of sanofi-aventis was held May 31, 2006.
-
-
NEW ELOXATIN® AND TAXOTERE® DATA IN SEVERAL TUMOR TYPESTO BE PRESENTED AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)
- 430 abstracts from studies involving Taxotere® or Eloxatin® accepted at the meetings scientific sessions -
-
ADJUVANTED FORMULATION OF SANOFI PASTEUR H5N1 PANDEMIC INFLUENZA VACCINE CANDIDATE DEMONSTRATES SIGNIFICANT IMMUNE RESPONSE
Lyon, France May 11, 2006 A study published online in The Lancet on May 11 demonstrated that multiple dosage formulations of a candidate H5N1 influenza vaccine developed by sanofi pasteur were well-tolerated and generated an immune response, with and without adjuvant. Of the formulations being tested, an alum-adjuvanted 30 microgram (µg) dosage generated the most substantive immune response (
-
PLAVIX® (clopidogrel) LAUNCHED IN JAPAN
Paris, France, May 9, 2006 - Sanofi-aventis announced today that PLAVIX® (clopidogrel) has been launched in Japan.
-
Sanofi-aventis: Results First quarter of 2006
First quarter of 2006: Sales growth of 9.6% on a reported basis and 4.9% on a comparable basis1 52.8% growth in adjusted EPS1 and 19.8% excluding selected items3
-
Läkemedlet Acomplia godkänns i Europa
Läkemedlet Acomplia (rimonabant) har idag fått så kallad positive opinion från den europeiska läkemedelsmyndigheten EMEA och förväntas därmed bli godkänt i Sverige och övriga Europa. Formellt beslut tas av EU-kommissionen senare i sommar. Sanofi-aventis räknar med att Acomplia kommer att finnas tillgänglig på den svenska marknaden i slutet av det här året.
-
First Quarter 2006 Sales & Earnings - Friday May 5, 2006
The 1st quarter 2006 sales & earnings will be released at 7.00 am (Paris time) and will be available online at http://www.sanofi-aventis.com.
-
TRANSFER OF ALL JAPANESE RIMONABANT RIGHTS TO SANOFI-AVENTIS
As part of its strategy to strengthen its presence in Japan, sanofi-aventis announced today that it has agreed with Astellas Pharma Inc. to accelerate the transfer of all rights to rimonabant in Japan from a joint-venture company held by the two groups to sanofi-aventis.
-
LANMET STUDY SHOWS LANTUS® PLUS METFORMIN TO BE EFFECTIVE AND WELL-TOLERATED IN INITIATING INSULIN THERAPY IN TYPE 2 DIABETES
Achieving good glycemic control with less hypoglycemia and less weight gain
-
TAXOTERE® RECEIVES POSITIVE OPINION
TAXOTERE® RECEIVES POSITIVE OPINION FROM THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE RECOMMENDING APPROVAL IN THE EUROPEAN UNION FOR METASTATIC STOMACH CANCER
-
TAXOTERE® RECEIVES U.S. FDA APPROVAL FOR USE IN ADVANCED STOMACH CANCER
TAXOTERE®-based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer
-
New therapy significantly reduces risk of repeat heart attack and death
Brigham and Womens Cardiac Group Finds Enoxaparin Strategy is Better Than Commonly Administered Blood Thinning Strategy For Heart Attacks - New therapy significantly reduces risk of repeat heart attack and death
Visa mer
Loading...